SBI Midcap Fund
The scheme aims to provide investors with opportunities for long term growth in capital along with the liquidity of an open-ended scheme by investing predominantly in a well-diversified basket of equity stocks of Midcap companies.
Growthvine rating: 2/5 — ranked #24 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹229.87 (as of 2026-10-01) |
|---|
| AUM | ₹24,518 Cr |
|---|
| Expense ratio | 1.38% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Bhavin Vithlani |
|---|
| Exit load | 0.25% for redemption within 30 days. 0.1% for redemption after 30 days and within 90 days |
|---|
Performance & risk
| 5-year annualised return | 11.70% |
|---|
| Sharpe ratio | 0.4 |
|---|
| Standard deviation | 15.84% |
|---|
| Max drawdown | −78.65% |
|---|
| Alpha | -3.65 |
|---|
| Beta | 0.85 |
|---|
Over 5 years, captured 77.1% of NIFTY Midcap 150's upside and 76.8% of its downside.
Market cap allocation
| Large cap | 13.7% |
|---|
| Mid cap | 69.1% |
|---|
| Small cap | 17.2% |
|---|
Concentration
| Top 5 holdings | 15.0% |
|---|
| Top 10 holdings | 27.9% |
|---|
| Total holdings | 56 |
|---|
| Index overlap | 29.1% |
|---|
| Active share | 70.9% |
|---|
Top holdings
- CRISIL Ltd. — 3.3%
- Multi Commodity Exchange of India Ltd — 3.0%
- TORRENT POWER LIMITED — 3.0%
- Supreme Industries Ltd. — 2.9%
- Bharat Heavy Electricals Ltd. — 2.7%
- Biocon Ltd. — 2.6%
- Federal Bank Ltd. — 2.6%
- SUNDARAM FINANCE LTD — 2.6%
- FSN E-Commerce Ventures Limited — 2.6%
- ICICI Lombard General Insurance Company Limited — 2.6%
Top sectors
- Retail — 9.7%
- Pharma & Biotech — 9.7%
- Finance & Investments — 9.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −2.6% | Q4 (Bottom) | #28 of 31 |
| 2025 | 0.4% | Q3 | #21 of 29 |
| 2024 | 20.3% | Q4 (Bottom) | #26 of 29 |
| 2023 | 34.5% | Q3 | #19 of 28 |
| 2022 | 3.0% | Q2 | #10 of 22 |